CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rubius Therapeutics, a biotechnology company pioneering the creation of a new class of extraordinarily active, ready-to-use and life-changing cellular therapies, today announced that David Epstein, executive chairman of Rubius, will provide a corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference.
The presentation will take place at 7:30 a.m. PST (10:30 a.m. EST) on Monday, January 8, 2018 at the Westin St. Francis Hotel in San Francisco.
About Rubius Therapeutics
Rubius Therapeutics, a 2017 “Fierce 15” award winner, is creating RCTs™ as a new class of medicines. Leading applications include programs in cancer, enzyme deficiency diseases and the induction of tolerance to treat autoimmune disease. The company was conceived and launched by Flagship VentureLabs®, the innovation foundry where a team of scientific entrepreneurs systematically evolve enterprising ideas based upon previously undiscovered areas of science into real-world inventions and ventures. Rubius® was founded by Flagship Pioneering in 2014. For more information please visit www.rubiustx.com.
About RCT™ Products
RCT™ products are genetically engineered, enucleated red cells that are being developed to provide allogeneic, ready-to-use cellular therapies to patients across multiple therapeutic areas. The advantages of RCT products over other therapies include immuno-privileged presentation of proteins within or on the red cell, high target avidity and affinity, and long circulation half-life. Rubius RCTs exhibit fundamentally unique and potent biology; that have been engineered to replace missing enzymes for patients living with a variety of rare diseases, to kill tumors, and to upregulate or downregulate the immune system to treat both cancer and autoimmune disorders.